Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARS1 | P26639 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 9/20 | 0.53 |
| ▸ | CA2 | P00918 | 6/20 | 0.53 |
| ▸ | CA9 | Q16790 | 6/20 | 0.53 |
| ▸ | LARS1 | Q9P2J5 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 5/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.47 |
| ▸ | MMP14 | P50281 | 2/20 | 0.47 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 2/20 | 0.46 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP7 | P09237 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7344886 | 0.85 | TARS1 (0.42) | TARS1MMP2CA2CA9LARS1 | |
| SCHEMBL19792904 | 0.82 | LARS1 (0.78) | TARS1MMP2LARS1CTSKCTSS | |
| SCHEMBL7164038 | 0.80 | CTSK (0.62) | CTSKCTSSMMP13CA1 | |
| SCHEMBL7163244 | 0.79 | CTSK (0.46) | TARS1MMP2CA2CA9CTSK | |
| SCHEMBL7168553 | 0.78 | CTSK (0.42) | TARS1MMP2CA2CA9CTSK | |
| SCHEMBL7244091 | 0.78 | CTSK (0.46) | TARS1MMP2CA2CA9CTSK | |
| SCHEMBL7806101 | 0.78 | TARS1 (0.57) | TARS1MMP2CA2CA9LARS1 | |
| SCHEMBL7241035 | 0.78 | HSP90AA1 (0.43) | TARS1MMP2CA2CA9CTSK | |
| SCHEMBL7616420 | 0.77 | CTSK (0.44) | MMP2CA2CA9CTSKCTSS | |
| SCHEMBL6622127 | 0.77 | CTSK (0.47) | LARS1CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586466-B2 | Enzyme inhibitor for use in the treatment of bone, oral, arthritic, paget's and hypercalcemic diseases | SMITHKLINE BEECHAM CORPORATION | 2003-07-01 | — | — | US | disclosed |
| US-6562842-B2 | Osteoporosis, oral diseases | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | disclosed |
| US-20020173469-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-21 | — | — | US | disclosed |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | THOMPSON SCOTT KEVIN (US) | 2002-10-24 | — | — | US | disclosed |
| US-20020077455-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-06-20 | — | — | US | disclosed |
| US-6331542-B1 | TREATING DISEASES CHARACTERIZED BY BONE LOSS OR EXCESSIVE CARTILAGE OR MATRIX DEGRADATION | SMITHKLINE BEECHAM CORPORATION | 2001-12-18 | — | — | US | disclosed |
| US-6284777-B1 | BONE DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2001-09-04 | — | — | US | disclosed |
| US-6232342-B1 | CATHEPSIN K INHIBITOR FOR TREATING OSTEOPOROSIS, GINGIVITIS, PERIODONTITIS, ARTHRITIS, OSTEOARTHRITIS RHEUMATOID ARTHRITIS, PAGET'S DISEASE, HYPERCALCEMIA OF MALIGNANCY AND METABOLIC BONE DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-05-15 | — | — | US | disclosed |
| EP-1068304-A4 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORP (US) | 2001-05-09 | — | — | EP | disclosed |
| EP-1068304-A1 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORPORATION (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6057362-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-5998470-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999053039-A1 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-21 | — | — | WO | disclosed |
| EP-0934291-A4 | — | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1997016177-A9 | METHOD OF INHIBITING CATHEPSIN K | — | 1997-07-24 | — | — | WO | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | PEPD, PREP, CPN1 | TARS1 1905/4885MMP2 119/4885CA2 187/4885 |
| US-20020173469-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | TARS1 3880/4885MMP2 26/4885CA2 124/4885 |
| US-20020077455-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | TARS1 3880/4885MMP2 26/4885CA2 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.